News

Oncolytics Biotech® Engages Experts on Pancreatic Cancer Research

Oncolytics Biotech® Engages Experts on Pancreatic Cancer Research

Oncolytics Biotech® Engages Experts on Pancreatic Cancer Research

Oncolytics Biotech Inc. (NASDAQ: ONCY) is set to host an important key opinion leader (KOL) webinar focused on advancements in treatments for pancreatic and gastrointestinal cancers. This event will bring together leading experts in the field to discuss the promising immunotherapy agent, pelareorep, used in the treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC).

Insightful KOL Webinar Information

The webinar highlights a discussion scheduled for July 22, 2025, at 1:00 p.m. ET, fostering a collaborative environment where expertise meets innovation. Attendees can expect key insights from notable KOLs, including Dirk Arnold, M.D., Ph.D., Alexander Eggermont, M.D., Ph.D., Sanjay Goel, M.D., M.S., FASCO, and Devalingam Mahalingam, M.D., Ph.D. These experts will delve into pelareorep's existing clinical data and its potential as a leading immunotherapeutic option in specific cancer types.

Joining Forces with Expert Voices

Panelists will comprise KOLs representing prestigious institutions, including Asklepios Tumorzentrum Hamburg and the Rutgers Cancer Institute of New Jersey. Their backgrounds range from research in immunotherapy to innovations in drug development, ensuring a session rich in knowledge. The discussion will be complemented by a Q&A session, allowing participants to engage directly with the experts and gain an in-depth understanding of the evolving landscape of cancer treatment.

Meet the Experts

Dr. Dirk Arnold

Dr. Dirk Arnold is a renowned expert and Director of Asklepios Tumorzentrum Hamburg. With a robust research focus on gastrointestinal cancers and immunotherapy, he has significantly contributed to clinical trials like the GOBLET trial. His academic journey spans reputable institutions where he earned his medical degree and later specialized in oncology.

Dr. Alexander Eggermont

Another prominent figure, Dr. Alexander Eggermont, serves as a Professor of Clinical & Translational Immunotherapy. His illustrious career includes leadership roles at Gustave Roussy Cancer Campus in France and comprehensive research contributions, which have gained international recognition through numerous peer-reviewed publications.

The Role of Pelareorep in Cancer Treatment

Pelareorep, an intravenously delivered immunotherapeutic agent, has shown encouraging results in clinical studies for metastatic breast cancer and pancreatic cancer. Oncolytics has focused much of its research on how pelareorep restructures the immune response to target cancerous cells effectively, altering the tumor microenvironment from “cold” to “hot.” This modification prompts a more robust immune attack against tumors, enhancing overall treatment efficacy.

Combination Trials Underway

As part of its commitment to developing effective cancer treatments, Oncolytics is continuously conducting and planning clinical trials combining pelareorep with other approved oncology therapies. This strategy has the potential to pave the way for innovative solutions for patients battling metastatic conditions.

About Oncolytics Biotech Inc.

Founded with the vision of advancing cancer immunotherapy, Oncolytics is at the forefront of biopharmaceutical innovation. The company’s pipeline highlights pelareorep’s capabilities across several malignancies, leading to their entry into registrational studies under the FDA's Fast Track designation. As it empowers scientists and clinicians to understand and combat cancer more effectively, the impact of Oncolytics Biotech extends far beyond mere numbers.

Frequently Asked Questions

What is the focus of the Oncolytics KOL webinar?

The webinar will focus on the use of pelareorep in treating pancreatic and gastrointestinal cancers, featuring discussions with leading medical experts.

Who are the KOLs participating in the webinar?

Participating KOLs include Dr. Dirk Arnold, Dr. Alexander Eggermont, Dr. Sanjay Goel, and Dr. Devalingam Mahalingam, all experts in oncology and immunotherapy.

What is pelareorep?

Pelareorep is an immunotherapeutic agent developed by Oncolytics Biotech, aimed at enhancing anti-cancer immune responses and used in treating various solid tumors.

How can one participate in the webinar?

Interested individuals can register for the webinar to gain insights into the latest advancements in cancer treatment.

What is the significance of the clinical trials mentioned?

These trials are essential for validating the effectiveness of pelareorep and exploring its potential when combined with other therapeutic agents in treating challenging cancers.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Movement Elevates a Longtime Insider as Its New CEO

Updated Category News Views 9

Chalk dust rarely makes headlines, yet this is the sort of leadership change that can decide whether a consumer brand keeps its footing. Movement Climbing, Yoga and Fitness named Ryan Sewell chief executive officer effective November 18, 2026, with Anne-Worley Moelter moving into the chairperson role. It is a conspicuously internal handoff: Sewell started at the Boulder...

Continue Reading
Insta360 Tests Holiday Demand With $170 Gear Discounts

Updated Category News Views 161

A discount banner can reveal plenty about a hardware brand's priorities, and Insta360's latest Black Friday push is plainly built to put more of its ecosystem into customers' hands. The company is advertising savings of up to US$170 across cameras, gimbals, microphones, webcams, and accessories, with the promotion available for a limited time through its own store and...

Continue Reading
SciBase Sets Its 2027 AGM Nominating Committee Early

Updated Category News Views 34

Four names on a committee roster rarely make anyone pound the table, and they should not. Still, SciBase Holding has put an important bit of corporate housekeeping in place for its 2027 Annual General Meeting: the nominating committee that will handle shareholder-facing governance work ahead of the May 20 meeting in Stockholm. For a small listed medical-technology...

Continue Reading
MFB Bancorp Offering Puts Chicago Bank Conversion First

Updated Category News Views 23

A small Chicago thrift is asking investors to fund a corporate makeover, and the fine print matters more than the $10 sticker price. MFB Bancorp has commenced an offering tied to the planned conversion of Mutual Federal Bancorp, MHC from a mutual holding company structure into a stock holding company. This is not some high-growth bank story with a shiny new branch map. It...

Continue Reading
Everyday Dose Tests Coffee in a New Pocket Format Today

Updated Category News Views 22

Coffee has finally wandered into the candy aisle, and I cannot decide whether that is clever or mildly exhausting. Everyday Dose and Austin-based Le Lick have launched Le Latte, a limited-batch coffee-flavored electrolyte lollipop aimed at adults who want caffeine without hauling around a cup. It is an odd little product, sure, but odd is often where consumer brands find...

Continue Reading
Rox Taps Dynamics 365 Without Forcing a CRM Reset Yet

Updated Category News Views 89

Enterprise software buyers hate renovations when a useful extension will do. Rox’s new integration with Microsoft Dynamics 365 Sales, announced November 19, 2026, is built around that unglamorous but very real fact. The company is not asking a Global 2000 sales organization to rip out its customer system, retrain everybody, and pray an AI layer somehow pays for the...

Continue Reading
Scientific Games Takes Big Buck Hunter to Lotteries

Updated Category News Views 76

A mounted arcade cabinet is an odd place to find lottery growth, yet Scientific Games may be onto something with its exclusive Big Buck Hunter licensing deal. Announced November 19, 2026, the arrangement lets the company carry a 26-year-old arcade franchise into U.S. and Canadian instant scratch games, Fast Play, draw games, digital products and second-chance promotions....

Continue Reading
LiberNovo's European Black Friday Sale Tests Demand

Updated Category News Views 155

A €1,339 chair has no business pretending it is an impulse buy, which is exactly why LiberNovo’s Black Friday push deserves a closer look. The Hong Kong-based ergonomic-chair seller has rolled out its Black Friday sale across the European Union and United Kingdom, with the campaign ending November 30 at 23:59 CET in the EU and 23:59 GMT in the UK. This is a...

Continue Reading
Vail Resorts Bets on Music to Deepen Epic Pass Demand

Updated Category News Views 40

A bass drop at 11,000 feet is not merely a party trick when you run 42 mountain resorts. Vail Resorts is putting live music, après programming and destination events squarely beside skiing and riding for winter 2026-27, and the business logic is pretty plain: give people another reason to buy early, stay longer and return with friends. For investors watching MTN, this is...

Continue Reading
DoorDash Grocery Tools Need a Hard Look Before Checkout

Updated Category News Views 95

A grocery cart built in thirty seconds can still nick your wallet all week. That is the part buried beneath the convenience pitch around DoorDash's grocery tools: planning is useful, but convenience only earns its keep when the final basket, delivery charge, substitutions, and timing actually line up. The 2026 review from Expert Consumers highlights features that are...

Continue Reading

Top 5 Most Recently Viewed Articles

Jyske Realkredit A/S Announces New Bond Listing Details

Updated Category News Views 192

Key Announcement about New Bond Listings On August 20, Jyske Realkredit A/S is set to introduce new bonds to the market. This announcement signals a pivotal moment for investors and the financial community alike. The company is preparing to list a novel type of Covered Bond (SDO) and a Mortgage Bond (RO), which could have significant implications for the current market...

Continue Reading
Maze Therapeutics Engages Investors at Major BioConnect Event

Updated Category News Views 168

Maze Therapeutics Engages Investors at a Major Event Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company, is making waves in the healthcare industry with its innovative approach to developing small molecule precision medicines. Their focus on addressing renal, metabolic, and cardiovascular diseases underscores the company's commitment to...

Continue Reading
Iterum Therapeutics Successfully Completes $5 Million Offering

Updated Category News Views 161

Iterum Therapeutics Completes Significant Offering Iterum Therapeutics plc (NASDAQ: ITRM), a biopharmaceutical company dedicated to creating innovative solutions against multi-drug resistant pathogens, has officially announced the successful closure of its recent direct offering. This strategic fundraising effort resulted in the sale of 5,555,556 ordinary shares, or the...

Continue Reading
Shopify Achieves Unprecedented Milestone with $14.6 Billion Sales

Updated Category News Views 210

Shopify's Impressive Holiday Sales Growth Shopify Inc. (NASDAQ: SHOP) has recently announced a phenomenal achievement, showcasing that merchants on its platform generated a staggering $14.6 billion in sales during the holiday shopping weekend. This impressive figure marks a magnificent 27% increase compared to the previous year, with approximately 81 million customers...

Continue Reading
Hotel Okura and AWC Set to Launch Unique Ryokan Hotels

Updated Category News Views 305

Hotel Okura and AWC Announce New Ryokan-Style Hotels In an exciting development for Thailand's hospitality sector, Hotel Okura Co., Ltd., a leading global player in the Japanese hotel industry, has partnered with Asset World Corporation (AWC). This collaboration will bring two new ryokan-style hotels to Chiang Mai and Bangkok, both slated to open by the year 2028. This...

Continue Reading